Project 1. GSK shall make the non-refundable, non-creditable milestone payments to Anacor that are set forth below in either Section 6.3.1(a) or Section 6.3.1(b), as applicable, upon occurrence of the corresponding milestone event with respect to a Collaboration Compound resulting from Project 1. Such payments shall be subject to the additional terms and conditions set forth in Sections 6.3.1(c), 6.3.5, 6.8, 6.10 and 6.12.
Project 1. Subject to Section 6.5.3, 6.9, 6.10 and 6.12, with respect to Products containing GSK Development Compounds arising solely out of Project 1, GSK shall pay to Anacor [***] in the Territory at the royalty rates as set forth in the table below. The applicable royalty rates for a particular Product shall depending on whether GSK elected the GSK Development Compound contained in such Product by exercising a Candidate Selection Option or a PoC Option. Annual Net Sales in the Territory Royalty Rate—[***] Option(1) Royalty Rate— [***] Option [***]
Project 1. Was the project completed within past three years? 2. Purpose of project? 3. Was the system supplying water prior to repair or upgrade? 4. If this is a Guzzler fill in the blanks below. □ Yes □ New well □ Yes Apron Size: □ No* □ New Dirt Tank □ No* *If No skip the rest of section □ New Catchment Guzzler *Skip question if new water development. Storage Gallons: □ Repair or upgrade existing water system. *Must answer following question.
Project 1. GSK shall make the non-refundable, non-creditable milestone payments to Anacor that are set forth below in either Section 6.3.1(a) or Section 6.3.1(b), as applicable, upon occurrence of the corresponding milestone event with respect to a Collaboration Compound resulting from Project 1. Such payments shall be subject to the additional terms and conditions set forth in Sections 6.3.1(c), 6.3.5, 6.8, 6.10 and 6.12. [***] THE SYMBOL [***] IS USED TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.
Project 1. A. UNIVERSITY GMP manufacturing of a cell-based vaccine (BriaVax SV-BR-l-GM) and a control cell line scope of work and cost estimates given to COMPANY’S employee on May 14, 2015: Corporate Office – US Briacell Therapeutics Corp. 800 Xxxxx Xxxxxx Xxxxxxxx, XX 00000 Tel: 800-000-0000 FAX: 400-000-0000 Dx. Xxxxxxx X. Wiseman Chairman and CEO Briacell Therapeutics Corp. 8000 Xxxxxxxx Xxxx. Xxxxx 000 Xxxxxxx Xxxxx, XX 00000 Mobile: 300-000-0000 Email: cx@xxxxxxxx.xxx
Project 1
